Wednesday, 14 December 2011

The George Pantziarka TP53 Trust

TP53 is a gene that functions as a tumour suppressor. One of its jobs is to create the p53 protein, which acts to kill cells that have become cancerous. When the TP53 gene goes wrong, it means the body loses one of the key mechanisms it has for stopping damaged cells becoming cancers. Many people who develop cancer end up having the TP53 gene damaged in their tumours, but it functions normally in the rest of their body. However, there are some people who are born with a damaged TP53 gene, and for these people the risk of getting cancer is incredibly high. In many of these cases the damaged TP53 gene is inherited - it is passed down from parent to child.

Li Fraumeni Syndrome (LFS) is one of the most serious forms of inherited TP53 disorder. My son, George, had LFS, which we assume he inherited from his mother, who died of ovarian cancer at the age of 29, when George was just over a year old. As I have written before, we did not know that George had LFS until after he was diagnosed with his third cancer - the osteosarcoma which ultimately killed him.

While LFS and other congenital TP53 disorders are rare, the fact remains that there is little awareness of the issue, both amongst the general population and also amongst the medical profession. There are no support groups, no charities, no central information resources and currently no central registry of sufferers. For those families with LFS or other TP53 disorders, it can be a lonely and frightening existence, with children and adults alike succumbing to one or more cancers.

Having discussed the issue with a number of doctors and researchers, we have decided to create the George Pantziarka TP53 Trust, in George's memory. The aim is to provide support to families and individuals, to provide information to all, and to help foster understanding and research into the condition.

As a first step we will be launching a web-site and forum in the new year. The plan is to use the site to bring together all those affected or interested in the condition. Further down the line we hope to register the Trust as a charity so that we can expand the range of activities that we can undertake.

For now, any offers of support would be greatly appreciated.

Friday, 9 December 2011

Open Access To Research

Regular readers of this blog will be aware that I spend a lot of time reading and reviewing the research literature on cancer. I see translating that research into plainer language that is more accessible to the average person is one of the things that this site can usefully do. As such having access to the research papers is essential. Unfortunately getting hold of papers is not always an easy task. Science journals are incredibly expensive to subscribe to (typically many hundreds of pounds a year) and there are a lot of them. The whole system is geared towards providing access to research to academics and researcher (mostly) via university or institutional libraries. Without this library access an individual can buy a copy of a specific paper - but here the cost ranges from a few tens of pounds to over a hundred. For most people this is prohibitive, especially if you are a cancer patient or carer and are doing a lot of reading.

The thing is, a lot of that research is publicly funded. We pay for it through our taxes - indirectly, of course, in the form of research grants and so on. So, as members of the public we pay for the research but we can't always get to read the results of that research. However you look at it, this is a really poor state of affairs, particularly when it comes to medical research.

It's not all bad. There are an increasing number of journals which are published on an open access basis. In other words the journals publish their work online and for free. Some journals, such as BMC Cancer, are well-established now, and publish high quality work that can be downloaded by anybody. In other cases journals make older articles available for free, so that for the first six months or a year a paper must be paid for, but after that it's free. Another option that some journals have adopted is to make selected articles free - which is good if it's one that you're looking for but rubbish if not. Finally, there are also some journals who allow access to articles by patients for free, but everyone else has to pay. Normally this involves filling in an online form to gain access to the article.

Wednesday, 7 December 2011

Cancer and lifestyle choices

The headlines are startling: over 40% of cancers are down to lifestyle. The opening paragraph of the BBC News report states it bluntly:
Nearly half of cancers diagnosed in the UK each year - over 130,000 in total - are caused by avoidable life choices including smoking, drinking and eating the wrong things, a review reveals.
For those with cancer, or who have family or friends suffering from the disease, this makes for grim reading. Because, like it or not, there's a moralistic sub-text here: in over 40% of cases, cancer is the fault of the patient. If only they'd chosen the right life-style, they wouldn't be sick.

Now, that isn't what the articles say, but it's a clear implication. Before we go any further though, perhaps we ought to back up a little and ask what the science really says...

Firstly, we have to be clear that what we're talking about here are projections based on a series of mathematical models. These projections take a series of risk factors - say smoking or alcohol consumption - and then compare the increased risks of developing cancer based on comparing current consumption levels and what are considered the 'optimum' levels. So, for example, you take the additional risk of developing cancer per unit of alcohol, the difference between current consumption and the ideal level and calculate the increased risk. Now take that increased risk and multiply by population and you get your projected number of cancer patients. It's a bit more complicated than that, of course, but in principle that's how it works. Add an additional set of factors for different types of cancer, and you've got a cascade of different variables that make up that final scary number.

So, all of this is subject to many different assumptions about risk factors, current consumption levels, ideal consumption levels, population growth etc.

Thursday, 24 November 2011

Arginine, Glioblastoma and the Immune System


An interesting piece of work came to my attention earlier this week that I think is worth sharing for a number of reasons. Firstly, I think it illustrates a way of working that really should be encouraged - it has significance beyond the specific interventions mentioned. Secondly, I think there are lessons here for those who are interested in anti-cancer agents not patented by the drug companies (such as curcumin, quercetin, resveratrol etc). Finally, it has interest for those suffering from glioblastoma (GBM) - a form of brain cancer that is particularly aggressive and hard to treat.

The work in question looked specifically at the phenomenon of immune suppression in GBM patients, and let's note at the outset that immune suppression is a problem for all cancer patients, not just those with GBM. Brain cancer patients - not just those with GBM - at the University of Colorado Hospital had blood taken and analysed, along with blood from non-cancer patients. Analysis revealed that the blood from GBM patients in particular showed lower levels of T-cell proliferation and released lower levels of interferon-gamma compared to normal blood samples - in other words they had lower levels of immune function. The specific forms of this immune suppression were worked out in a series of lab experiments that ultimately showed that one of the factors associated with this suppression was a high level of the enzyme Arginase I (ArgI). This enzyme consumes the amino acid Arginine, which is essential for T-cell activation.

So far so good - it's interesting, in an academic way, but so what? The experimenters then took the next step and looked at chemically blocking ArgI with a specific drug. Doing this improved the immune response in the test tube. Levels of interferon-gamma rose to normal levels. The next step, however, is where it gets really interesting from a patient point of view. Rather than blocking ArgI with a drug, the team looked at increasing levels of Arginine (which is what ArgI consumes). By adding more Arginine the immune response improved. In simple terms the ArgI was basically using up the circulating Arginine and thus starving the T-cells of it, but by increasing the amount of Arginine the researchers showed that they could 'feed' the ArgI and have enough left over to be used by the T-cells, which could become activated as normal.

Wednesday, 23 November 2011

Q&A With Dr Anthony Howell - The Reverse Warburg Effect

One of the fundamental ideas in cancer has been that cancer and normal cells differ in their metabolism. First proposed by Nobel prize-winner Otto Warburg in 1924, the 'Warburg Effect' is the hypothesis that cancer cells generate energy by the non-oxidative (without oxygen) breakdown of glucose (a process called glycolysis). This is in contrast to normal cells, which generate energy through an oxygen-dependent pathway. Tumours use the non-oxidative pathway, which is less efficient than normal metabolism, even in conditions where there is plenty of oxygen available. We can see this greediness for glucose in PET scans, for example, where radioactively labelled sugar is sucked up by tumours and not by normal tissue.

For many years the Warburg effect has been investigated as a possible Achilles heel for tumours, and there is still lots of work being done on ways to attack tumours by interrupting this glycolytic process. Such work ranges from dietary interventions (see for example the article on diets and cancer, and the interview with Dr Gerald Krystal), to looking for drugs which disrupt the process at different points.

However, in recent years Dr Michael Lisanti and a group of colleagues have proposed a fundamental re-appraisal of the theory. They have proposed the cancer cells in advanced solid tumours are able to induce the Warburg Effect in the cells that surround them (the tumour stroma), and that they then consume the by-products of glycolysis produced by the stromal cells. In other words they cannibalise the tissues around themselves, inducing the Warburg Effect so that they can feed off the nutrients produced by the stromal cells. They have termed this new theory, which is a radical departure from what is currently accepted, the 'Reverse Warburg Effect'.

For those who wish to learn more there are a number of freely available papers by Lisanti and co available via PubMed.

Dr Anthony Howell is one of Lisanti's co-authors and a researcher and clinician based in Manchester. He has kindly agreed to an interview so that we can learn more about this new theory and what it may mean in terms of clinical practice. Although the language in this interview is more technical than much of what is published on this site, I feel it's important to bring these new theories and results to as wide an audience as possible.

PP: A recent editorial in the journal Cell Cycle described the work of Michael Lisanti, yourself and others as ‘iconoclastic’. Just how revolutionary is the theory of the ‘reverse Warburg’ effect and the idea of ‘cancer as a parasite’?

AH: Warburg was a great scientist as reflected in the award of the Nobel Prize for his pioneering work on tumour metabolism. His major contribution was to show that tumour cells showed enhanced glycolysis and he thus assumed that mitochondrial respiration was impaired in tumour cells. It certainly looks like this when you put tumour cell lines such as the breast MCF-7 cell line into culture by themselves. These cells have few mitochondria and there is increase in the sugar degradation glycolytic pathway. What Michael Lisanti and his colleagues have shown is that this may be an artefact of culturing the cells alone. When co-cultured with human fibroblasts, the MCF-7 cells synthesise mitochondria and thus use oxidative phosphorylation as their main source of energy. In the body tumour cells are always associated with what is called a supportive stroma derived from the host, so that the co-culture system is a better mimic of what might be happening in-vivo, and indeed we find up-regulation of mitochondria in most breast cancers compared with normal breast tissue. Cultured alone the fibroblasts have a large number of mitochondria. However, when co-cultured with tumour cells they degrade the mitochondria and depend upon gylcolysis. So all these observation are opposite to Warburg’s observations. It is as if the Warburg effect occurs in tumour associated fibroblasts rather than the tumour cells themselves which has lead Lisanti to call what is happening in co-culture ‘The Reverse Warburg Effect’. I think this is where the implication that these observations are iconoclastic comes from.

Tuesday, 22 November 2011

UK Clinical Trials Gateway

I have previously written about how to search for clinical trials, describing the difference between Phase I, II and III trials, as well as how to use the US National Institutes of Health Clinical Trials database (http://clinicaltrials.gov/). However, the fact it's currently very difficult to find out what trials are going on in the country as a whole. What's missing is a central database of all clinical trials. A step in the right direction is the UK Clinical Trials Gateway (http://www.ukctg.nihr.ac.uk/default.aspx).

While not a central registry itself, the UKCTG does enable the user to search a number of international registries through the site. Users can search on specific diseases (e.g. a specific type of cancer, like lung cancer), specific drugs (e.g. celecoxib) or other forms of therapy (e.g. photodynamic therapy), as well as combinations such as "celecoxib AND cancer". For each record returned by the search you can find out whether the trial is recruiting patients, where the trial is taking place and more details on the actual treatment itself. For patients looking for a trial it's a really useful place to start.

However, there is still room for a central registry of clinical trials. Not only would it provide doctors and patients with a single database to query for all trials in the UK, it would also allow us to track the level of activity for different diseases. For example doing a query on the UKCTG shows that there are no trials for osteosarcoma in the UK, which is sad if true, but I know that there are some trials on-going at the moment (the SUCCEED trial, run by Merck and Ariad Pharmaceuticals).

Just as importantly a central registry will enable us to see what trials are aiming to do, what protocol they use and what outcomes they are tracking. With this information we can see which trials publish their results, and also see whether they succeed in what they set out to do or whether they changed what they say they are looking for in order to present the best possible gloss on their results. And yes, this is something that does happen...

Until then, at least the UKCTG provides us with yet another useful tool to help patients and their doctors find appropriate clinical trial information.

Friday, 11 November 2011

Test Tube Cancer Cells and People

Test tube cancer cells vs. real cancer cells

In a previous article (How To Read A Cancer Paper Part 1 - ), I looked at the pitfalls of in vitro studies. These are studies performed in the lab that look at cancer cells under glass (actually a Petri dish rather than a test tube as such). These studies - and there are tens of thousands of them - are often performed to see how cancer cells respond to specific anti-cancer agents. And, as I said in the article:

...you have to take these test tube studies with a huge pinch of salt. In the test tube substance X kills cancer, but that really doesn’t mean much in the real world. At most it gives you reason to carry on looking at substance X in more detail, but that’s about it.

The obvious alternative is to look at in vivo studies, which are discussed in the second article in the series. These are studies that use animals (normally mice or rats), with real tumours rather than cells grown under glass. While these are better, there are still major pitfalls, which I discuss in the article. One problem that I highlight is that the tumours that are grown are derived from standard cell lines. These are cancer cells that have been grown for year after year after year under lab conditions. The intention is to have some standard cell lines that are indicative of the tumour type or sub-type (e.g. androgen responsive prostate cancer, triple negative breast cancer etc). A key point I make in that article is:

Furthermore, cancer cells mutate and adapt, so cells that have been taken from a patient biopsy twenty or thirty years ago and then kept under glass for generation after generation will have changed in order to survive in the test tube environment.

A new study, published in the Proceedings of the National Academy of Sciences, looks at precisely this issue and comes to a disturbing conclusion. The experimenters were specifically looking at cancer cells that are drug-resistant. This is of major clinical importance as the fact is that we still don't fully understand why some cells can become resistant to anti-cancer drugs. Using state of the art technology, the researchers took a panel of standard cell lines and checked which genes are expressed. They did this both in the test tube and also from tumours grown in animals from these same standard cell lines. They then compared these with a set of cells taken directly from patient biopsies. The results are clear:

No correlation was found between clinical samples and established cancer cell lines....all of the cell lines, grown either in vitro or in vivo, bear more resemblance to each other, regardless of the tissue of origin, than to the clinical samples they are supposed to model.

In other words, the standard cell lines, originally from different types of tumour, have come to resemble each other genetically, whether used in the test tube or implanted in animals. They resemble each other more than they resemble 'live' samples taken from cancer patients.